195 related articles for article (PubMed ID: 34155608)
21. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
22. RANIBIZUMAB FOR RETINAL VEIN OCCLUSION: Predictive Factors and Long-Term Outcomes in Real-Life Data.
Chatziralli I; Theodossiadis G; Chatzirallis A; Parikakis E; Mitropoulos P; Theodossiadis P
Retina; 2018 Mar; 38(3):559-568. PubMed ID: 28248827
[TBL] [Abstract][Full Text] [Related]
23. Razumab -- the role of biosimilars for the treatment of retinal diseases.
Ferro Desideri L; Cutolo CA; Traverso CE; Nicolò M
Drugs Today (Barc); 2021 Aug; 57(8):499-505. PubMed ID: 34405207
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of Pro Re Nata regimen without loading dose ranibizumab injections in retinal vein occlusion.
Unsal E; Eltutar K; Sultan P; Gungel H
Pak J Med Sci; 2015; 31(3):510-5. PubMed ID: 26150834
[TBL] [Abstract][Full Text] [Related]
25. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients.
Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425
[TBL] [Abstract][Full Text] [Related]
26. Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases.
Chakraborty D; Stewart MW; Sheth JU; Sinha TK; Boral S; Das A; Mondal S; Mukherjee A
Ophthalmol Ther; 2021 Jun; 10(2):337-348. PubMed ID: 33864599
[TBL] [Abstract][Full Text] [Related]
27. An efficacy analysis of anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to multifocal choroiditis and comparison with wet age-related macular degeneration.
Feng L; Hu JH; Chen J; Xie X
J Zhejiang Univ Sci B; 2018 Apr.; 19(4):327-332. PubMed ID: 29616508
[TBL] [Abstract][Full Text] [Related]
28. Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study.
Massin P; Creuzot-Garcher C; Kodjikian L; Girmens JF; Delcourt C; Fajnkuchen F; Glacet-Bernard A; Guillausseau PJ; Ponthieux A; Blin P; Grelaud A
Ophthalmic Res; 2019; 62(2):101-110. PubMed ID: 30928985
[TBL] [Abstract][Full Text] [Related]
29. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
30. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion.
Manousaridis K; Peter S; Mennel S
Int Ophthalmol; 2017 Feb; 37(1):47-53. PubMed ID: 27043320
[TBL] [Abstract][Full Text] [Related]
31. Current perspectives on ranibizumab.
Dedania VS; Bakri SJ
Clin Ophthalmol; 2015; 9():533-42. PubMed ID: 25848203
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ranibizumab and subthreshold micropulse laser in treatment of macular edema secondary to branch retinal vein occlusion.
Buyru Özkurt Y; Akkaya S; Aksoy S; Şimşek MH
Eur J Ophthalmol; 2018 Nov; 28(6):690-696. PubMed ID: 29696993
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice.
Plaza-Ramos P; Borque E; García-Layana A
PLoS One; 2019; 14(10):e0223793. PubMed ID: 31644594
[TBL] [Abstract][Full Text] [Related]
35. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
36. Intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration.
Roller AB; Amaro MH
Arq Bras Oftalmol; 2009; 72(5):677-81. PubMed ID: 20027409
[TBL] [Abstract][Full Text] [Related]
37. Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion.
Yiu G; Welch RJ; Wang Y; Wang Z; Wang PW; Haskova Z
Ophthalmol Retina; 2020 Jan; 4(1):67-76. PubMed ID: 31669329
[TBL] [Abstract][Full Text] [Related]
38. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
39. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years.
Spielberg L; Leys A
Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659
[TBL] [Abstract][Full Text] [Related]
40. Comparing retinal thickness measurements using automated fast macular thickness map versus six-radial line scans with manual measurements.
Taban M; Sharma S; Williams DR; Waheed N; Kaiser PK
Ophthalmology; 2009 May; 116(5):964-70. PubMed ID: 19410954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
